TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF THE GLOBAL VENOUS DISEASES TREATMENT MARKET 52
1.4 CURRENCY AND PRICING 54
1.5 LIMITATIONS 55
1.6 MARKETS COVERED 55
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 DBMR TRIPOD DATA VALIDATION MODEL 63
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.6 MULTIVARIATE MODELLING 67
2.7 MARKET END USER COVERAGE GRID 68
2.8 INSTRUMENT BASED LIFELINE CURVE 69
2.9 DBMR MARKET POSITION GRID 70
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTEL ANALYSIS 80
4.2 PORTER'S FIVE FORCES 81
5 GLOBAL VENOUS DISEASES TREATMENT MARKET, INDUSTRY INSIGHTS 82
6 EPIDEMIOLOGY 84
7 REGULATORY FRAMEWORK 85
8 MARKET OVERVIEW 88
8.1 DRIVERS 90
8.1.1 RISING INCIDENCES OF VENOUS DISEASES 90
8.1.2 RAPID CHANGES IN LIFESTYLE LEAD TO OBESITY RESULTING IN VENOUS DISEASES 90
8.1.3 INCREASE IN THE GERIATRIC POPULATION 91
8.1.4 TECHNOLOGICALLY ADVANCEMENT IN THE TREATMENT OF VENOUS DISEASES 92
8.2 RESTRAINTS 93
8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 93
8.2.2 INADEQUATE REIMBURSEMENT COVERAGE 93
8.3 OPPORTUNITIES 94
8.3.1 RISING AWARENESS TOWARDS VENOUS DISORDERS 94
8.3.2 NEED FOR PROPER DIAGNOSIS AND TREATMENT OF VENOUS DISEASES 94
8.3.3 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 95
8.3.4 OCCUPATIONAL LIFESTYLE INCREASES THE NEED FOR VENOUS DISEASE TREATMENT 95
8.4 CHALLENGES 96
8.4.1 HIGH COST ASSOCIATED WITH VENOUS DISEASE TREATMENT 96
8.4.2 SIDE EFFECTS AND RISK ASSOCIATED WITH DIFFERENT TREATMENT MODES 97
9 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY PRODUCT TYPE 98
9.1 OVERVIEW 99
9.2 SCLEROTHERAPY INJECTION 102
9.2.1 SCLEROTHERAPY, BY TYPE 102
9.2.1.1 INTRAVENOUS 103
9.2.1.2 INTRADERMAL 103
9.2.1.3 SUBCUTANEOUS 103
9.2.2 SUBCUTANEOUS, BY APPLICATION 103
9.2.2.1 MALFORMED LYMPHED VESSELS 103
9.2.2.2 HEMORRHOIDS 103
9.2.2.3 HYDROCELES 103
9.2.2.4 OTHERS 103
9.3 ABLATION DEVICES 103
9.3.1 THERMAL ABLATION 104
9.3.1.1 RADIOFREQUENCY 105
9.3.1.1.1 CATHETER MANIPULATION SYSTEMS 105
9.3.1.1.2 TEMPERATURE CONTROLLED 105
9.3.1.1.3 FLUID COOLED 106
9.3.1.2 LIGHT 106
9.3.1.2.1 EXCIMER LASERS 106
9.3.1.2.2 COLD LASERS 106
9.3.1.3 ULTRASOUND 106
9.3.1.3.1 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) 107
9.3.1.3.2 SHOCK WAVE LITHOTRIPSY 107
9.3.1.3.3 MAGNETIC RESONANCE IMAGING GUIDED FOCUSED ULTRASOUND (MRI-FUS) 107
9.3.1.3.4 ULTRASONIC SURGICAL SYSTEMS 107
9.3.1.4 RADIATION 107
9.3.1.4.1 STEREOTACTIC BODY RADIATION THERAPY 108
9.3.1.4.2 INTENSITY-MODULATED RADIATION THERAPY 108
9.3.1.4.3 STEREOTACTIC RADIOTHERAPY & RADIOSURGERY 108
9.3.1.4.4 IMAGE GUIDED RADIATION THERAPY 108
9.3.1.4.5 INTRAVASCULAR BRACHYTHERAPY 108
9.3.1.4.6 PROTON BEAM THERAPY 108
9.3.1.5 ELECTRICAL 108
9.3.1.5.1 ELECTRICAL ABLATORS 109
9.3.1.5.2 ELECTRONIC BRACHYTHERAPY 109
9.3.1.6 MICROWAVE 109
9.3.1.7 HYDROTHERMAL 109
9.3.2 NON-THERMAL ABLATION 109
9.3.2.1 CRYOABLATION 109
9.3.2.1.1 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 110
9.3.2.1.2 CRYOGEN SPRAY PROBE 110
9.3.2.1.3 TISSUE CONTACT PROBE 110
9.3.2.2 HYDROMECHANICAL ABLATION 110
9.4 VENOUS CLOSURE PRODUCTS 110
9.4.1 VENOUS CLOSURE PRODUCTS, BY PROCEDURE 111
9.4.1.1 INTERVENTIONAL CARDIOLOGY 111
9.4.1.2 INTERVENTIONAL RADIOLOGY 111
9.4.2 VENOUS CLOSURE PRODUCTS, BY TECHNOLOGY 111
9.4.2.1 FEMORAL ACCESS TECHNIQUE 112
9.4.2.2 RADIAL ACCESS TECHNIQUE 112
9.5 VENOUS STENTS 112
9.5.1 VENOUS STENTS, BY TECHNOLOGY 113
9.5.1.1 WALLSTENT TECHNOLOGY 113
9.5.1.2 ILIAC VEIN STENT TECHNOLOGY 113
9.5.2 VENOUS STENTS, BY APPLICATION 113
9.5.2.1 LEG 114
9.5.2.2 CHEST 114
9.5.2.3 ABDOMEN 114
9.5.2.4 OTHERS 114
9.6 MEDICATION 114
9.7 OTHERS 115
10 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY DISEASE TYPE 116
10.1 OVERVIEW 117
10.2 VARICOSE VEINS 120
10.3 DEEP VEIN THROMBOSIS (DVT) 120
10.4 PULMONARY EMBOLISM 121
10.5 CHRONIC VENOUS INSUFFICIENCY (CVI) 122
10.6 SUPERFICIAL THROMBOPHLEBITIS 122
10.7 OTHERS 123
11 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY TREATMENT TYPE 125
11.1 OVERVIEW 126
11.2 SCLEROTHERAPY 129
11.3 RADIOFREQUENCY ABLATION THERAPY 129
11.4 LASER TREATMENT 130
11.5 AMBULATORY PHLEBECTOMY 131
11.6 VEIN LIGATION AND STRIPPING 131
11.7 ANGIOPLASTY OR STENTING 132
11.8 SURGERIES 133
11.9 COMPRESSION THERAPY 133
11.10 VEINACTIVE MEDICATION 134
11.11 VENA CAVA FILTER 135
11.12 OTHER THERAPIES 136
12 GLOBAL VENOUS TREATMENT DISEASES MARKET, BY END USER 137
12.1 OVERVIEW 138
12.2 HOSPITALS 141
12.3 CLINICS 141
12.4 AMBULATORY SURGICAL CENTERS 142
12.5 OTHERS 143
13 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 144
13.1 OVERVIEW 145
13.2 DIRECT TENDER 148
13.3 RETAIL SALES 148
13.4 OTHERS 149
14 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY REGION 150
14.1 OVERVIEW 151
14.2 NORTH AMERICA 156
14.2.1 U.S. 166
14.2.2 CANADA 172
14.2.3 MEXICO 178
14.3 EUROPE 184
14.3.1 GERMANY 195
14.3.2 U.K. 201
14.3.3 FRANCE 207
14.3.4 ITALY 213
14.3.5 RUSSIA 219
14.3.6 SPAIN 225
14.3.7 TURKEY 231
14.3.8 NETHERLANDS 237
14.3.9 BELGIUM 243
14.3.10 SWITZERLAND 249
14.3.11 IRELAND 255
14.3.12 REST OF EUROPE 261
14.4 ASIA-PACIFIC 262
14.4.1 CHINA 272
14.4.2 JAPAN 278
14.4.3 INDIA 284
14.4.4 AUSTRALIA 290
14.4.5 INDONESIA 296
14.4.6 SINGAPORE 302
14.4.7 MALAYSIA 308
14.4.8 PHILIPPINES 314
14.4.9 SOUTH KOREA 320
14.4.10 THAILAND 326
14.4.11 REST OF ASIA-PACIFIC 332
14.5 SOUTH AMERICA 333
14.5.1 BRAZIL 344
14.5.2 ARGENTINA 350
14.5.3 REST OF SOUTH AMERICA 356
14.6 MIDDLE EAST & AFRICA 357
14.6.1 SOUTH AFRICA 368
14.6.2 SAUDI ARABIA 374
14.6.3 U.A.E. 380
14.6.4 EGYPT 386
14.6.5 ISRAEL 392
14.6.6 REST OF MIDDLE EAST AND AFRICA 398
15 GLOBAL VENOUS DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 399
15.1 COMPANY SHARE ANALYSIS: GLOBAL 399
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 400
15.3 COMPANY SHARE ANALYSIS: EUROPE 401
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 402
16 SWOT ANALYSIS 403
17 COMPANY PROFILE 404
17.1 MEDTRONIC 404
17.1.1 COMPANY SNAPSHOT 404
17.1.2 REVENUE ANALYSIS 404
17.1.3 COMPANY SHARE ANALYSIS 405
17.1.4 PRODUCT PORTFOLIO 405
17.1.5 RECENT DEVELOPMENTS 405
17.2 BOSTON SCIENTIFIC CORPORATION 406
17.2.1 COMPANY SNAPSHOT 406
17.2.2 REVENUE ANALYSIS 406
17.2.3 COMPANY SHARE ANALYSIS 407
17.2.4 PRODUCT PORTFOLIO 407
17.2.5 RECENT DEVELOPMENTS 408
17.3 VARIAN MEDICAL SYSTEMS, INC. 409
17.3.1 COMPANY SNAPSHOT 409
17.3.2 COMPANY SHARE ANALYSIS 409
17.3.3 PRODUCT PORTFOLIO 410
17.3.4 RECENT DEVELOPMENT 410
17.4 STRYKER 411
17.4.1 COMPANY SNAPSHOT 411
17.4.2 REVENUE ANALYSIS 411
17.4.3 COMPANY SHARE ANALYSIS 412
17.4.4 PRODUCT PORTFOLIO 412
17.4.5 RECENT DEVELOPMENT 412
17.5 KONINKLIJKE PHILIPS N.V. 413
17.5.1 COMPANY SNAPSHOT 413
17.5.2 REVENUE ANALYSIS 413
17.5.3 COMPANY SHARE ANALYSIS 414
17.5.4 PRODUCT PORTFOLIO 414
17.5.5 RECENT DEVELOPMENT 414
17.6 ABBOTT 415
17.6.1 COMPANY SNAPSHOT 415
17.6.2 REVENUE ANALYSIS 415
17.6.3 PRODUCT PORTFOLIO 416
17.6.4 RECENT DEVELOPMENT 416
17.7 ALMA LASERS 417
17.7.1 COMPANY SNAPSHOT 417
17.7.2 PRODUCT PORTFOLIO 417
17.7.3 RECENT DEVELOPMENT 417
17.8 ANGIODYNAMICS 418
17.8.1 COMPANY SNAPSHOT 418
17.8.2 REVENUE ANALYSIS 418
17.8.3 PRODUCT PORTFOLIO 419
17.8.4 RECENT DEVELOPMENT 419
17.9 B.BRAUN MELSUNGEN AG 420
17.9.1 COMPANY SNAPSHOT 420
17.9.2 REVENUE ANALYSIS 420
17.9.3 PRODUCT PORTFOLIO 421
17.9.4 RECENT DEVELOPMENTS 421
17.10 BAYLIS MEDICAL COMPANY, INC 422
17.10.1 COMPANY SNAPSHOT 422
17.10.2 PRODUCT PORTFOLIO 422
17.10.3 RECENT DEVELOPMENT 422
17.11 BD 423
17.11.1 COMPANY SNAPSHOT 423
17.11.2 REVENUE ANALYSIS 423
17.11.3 PRODUCT PORTFOLIO 424
17.11.4 RECENT DEVELOPMENT 424
17.12 CANDELA MEDICAL 425
17.12.1 COMPANY SNAPSHOT 425
17.12.2 PRODUCT PORTFOLIO 425
17.12.3 RECENT DEVELOPMENT 425

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.